Biotech Values

[DewDiligence]

GILD posts $3.48B in 2Q14 Sovaldi sales (+53% vs 1Q14):

http://finance.yahoo.com/news/gilead-sciences-announces-second-quarter-200500437.html

Of the $3.48B total, $3.0B was from the US, $400M was from France and Germany (the two large EU countries that have negotiated reimbursement rates), and about $80M was from the rest of the world.

In the US market, 60% of Sovaldi prescriptions were for GT1 patients (down from 70% in 1Q14), 25% for GT2, 10% for GT3, and 5% for GT4,5,6.